Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00392938 · ClinicalTrials.gov registry record
Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone
A clinical trial, sponsored by University of Washington.
- Completed
- Registry status
- 11
- Enrollment target
NCT00392938 is a clinical trial that has completed, run by University of Washington. The registered enrollment target is 11 participants.
The verdict
NCT00392938 has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- 11 participants
- Enrollment target
Study Summary
RATIONALE: Imaging procedures, such as PET scan, may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying carbon-11 acetate and fludeoxyglucose F 18 PET scan of the bone in patients with metastatic prostate cancer that has spread to the bone.
Interventions
- DRUG docetaxel
- DRUG antiandrogen therapy
- DIAGNOSTIC_TEST C-11 acetate PET scan
- DIAGNOSTIC_TEST F-18 FDG PET scan
- DIAGNOSTIC_TEST Tc-99m bone scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2005-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00392938
The ClinicalTrials.gov registry entry for NCT00392938 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which docetaxel is the first listed.
NCT00392938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00392938 about?
NCT00392938 is a clinical study titled "Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone". RATIONALE: Imaging procedures, such as PET scan, may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying carbon-11 acetate and fludeoxyglucose F 18 PET scan of the bone in patients with metastatic prostate cancer that has...
What is the current status of trial NCT00392938?
This trial is currently completed. The enrollment target is 11 participants. The study started on 2005-12.
What interventions are being tested in trial NCT00392938?
The interventions under investigation include: docetaxel (DRUG), antiandrogen therapy (DRUG), C-11 acetate PET scan (DIAGNOSTIC_TEST), F-18 FDG PET scan (DIAGNOSTIC_TEST), Tc-99m bone scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT00392938?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.